CSN Login
Members Online: 1

You are here

Metastatic Breast Cancer Survey - Tukysa (tucatinib)

Monday, March 1, 2021 - 11:00am
Your announcement.: 

My name of MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.

The Canadian government will soon be reviewing the use of Tukysa (tucatinib) to treat HER2-positive metastatic breast cancer and Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.

Does this survey apply to you?

We are looking for patients with HER2-positive locally advanced unresectable or metastatic breast cancer and patients who have been treated with Tukysa to talk about their treatment experience.


If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/Tukysa

If you would like to speak with us directly about your cancer or treatment experience, you can contact me at MJ@rethinkbreastcancer.com.

MJ DeCoteau
Founder + Executive Director
Rethink Breast Cancer



The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider.

Check the appropriate category for your announcement: 
Research study, clinical trial, focus group,etc (Requires IRB review and certification. See here for guidelines.)
Contact - First name: 
Contact - Last name: 
Subscribe to Comments for "Metastatic Breast Cancer Survey - Tukysa (tucatinib)"